Kirschner J - Search Results

1

A homozygous splice-site mutation in CARS2 is associated with progressive myoclonic epilepsy.

Hallmann K, Zsurka G, Moskau-Hartmann S, Kirschner J, Korinthenberg R, Ruppert AK, Ozdemir O, Weber Y, Becker F, Lerche H, Elger CE, Thiele H, Nürnberg P, Sander T, Kunz WS. Hallmann K, et al. Among authors: kirschner j. Neurology. 2014 Dec 2;83(23):2183-7. doi: 10.1212/WNL.0000000000001055. Epub 2014 Oct 31. Neurology. 2014. PMID: 25361775

2

Absence of transcallosal inhibition in adolescents with diplegic cerebral palsy.

Heinen F, Kirschner J, Fietzek U, Glocker FX, Mall V, Korinthenberg R. Heinen F, et al. Among authors: kirschner j. Muscle Nerve. 1999 Feb;22(2):255-7. doi: 10.1002/(sici)1097-4598(199902)22:2<255::aid-mus14>3.0.co;2-7. Muscle Nerve. 1999. PMID: 10024139

3

Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure.

Mall V, Heinen F, Kirschner J, Linder M, Stein S, Michaelis U, Bernius P, Lane M, Korinthenberg R. Mall V, et al. Among authors: kirschner j. J Child Neurol. 2000 Apr;15(4):214-7. doi: 10.1177/088307380001500402. J Child Neurol. 2000. PMID: 10805185 Clinical Trial.

4

Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option.

Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen F. Kirschner J, et al. J Neurol. 2001 Apr;248 Suppl 1:28-30. doi: 10.1007/pl00007815. J Neurol. 2001. PMID: 11357236 Review.

5

Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure.

Linder M, Schindler G, Michaelis U, Stein S, Kirschner J, Mall V, Berweck S, Korinthenberg R, Heinen F. Linder M, et al. Among authors: kirschner j. Eur J Neurol. 2001 Nov;8 Suppl 5:120-6. doi: 10.1046/j.1468-1331.2001.00044.x. Eur J Neurol. 2001. PMID: 11851740 Clinical Trial.

6

p.S143F mutation in lamin A/C: a new phenotype combining myopathy and progeria.

Kirschner J, Brune T, Wehnert M, Denecke J, Wasner C, Feuer A, Marquardt T, Ketelsen UP, Wieacker P, Bönnemann CG, Korinthenberg R. Kirschner J, et al. Ann Neurol. 2005 Jan;57(1):148-51. doi: 10.1002/ana.20359. Ann Neurol. 2005. PMID: 15622532

7

Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.

Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Korinthenberg R, et al. Among authors: kirschner j. Pediatrics. 2005 Jul;116(1):8-14. doi: 10.1542/peds.2004-1324. Pediatrics. 2005. PMID: 15995024 Clinical Trial.

8

'Why do children with cerebral palsy discontinue therapy with botulinum toxin A?'.

Linder-Lucht M, Kirschner J, Herrmann J, Geth K, Korinthenberg R, Berweck S, Heinen F, Mall V. Linder-Lucht M, et al. Among authors: kirschner j. Dev Med Child Neurol. 2006 Apr;48(4):319-20. doi: 10.1017/S0012162206000697. Dev Med Child Neurol. 2006. PMID: 16542523 Free article. No abstract available.

9

Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study.

Schessl J, Luther B, Kirschner J, Mauff G, Korinthenberg R. Schessl J, et al. Among authors: kirschner j. Eur J Pediatr. 2006 Sep;165(9):605-12. doi: 10.1007/s00431-006-0140-1. Epub 2006 May 12. Eur J Pediatr. 2006. PMID: 16691408

10

Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome.

Schessl J, Koga M, Funakoshi K, Kirschner J, Muellges W, Weishaupt A, Gold R, Korinthenberg R. Schessl J, et al. Among authors: kirschner j. Arch Dis Child. 2007 Jan;92(1):48-52. doi: 10.1136/adc.2006.098061. Epub 2006 Aug 18. Arch Dis Child. 2007. PMID: 16920757 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

503 results

Search Page